Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Scaringi Lecture Series in Speech Language Pathology - Research Talk
Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 51吃瓜网College Ave. Room 606
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
Project to create AI model for ALS receives G茅nome Qu茅bec funding
听
A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.
